Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Pacira Pharma (PCRX) Misses Q4 EPS by 5c, Sales Beat
February 25, 2016 7:34 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.22, $0.05 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $69.3 million versus the consensus estimate of $68.4 million.
We finished 2015 with a solid performance in spite of the challenges we faced this past... More
